Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 242KB)
Why become a member?

New drug formulation for Fibromyalgia moves forward

Thursday 26 April 2012

 

From About.com's Adrienne Dellwo:

 

TabletsNew Drug Formulation for Fibromyalgia Moves Forward

By Adrienne Dellwo, About.com Guide
April 9, 2012

Research Brief

An old drug in a new form is moving forward through trials, and the manufacturer hopes it will eventually be approved for treating fibromyalgia.

TONIX Pharmaceticals has announced that it's completed an early phase of testing for what's being called TNX-102. (This name is a research designation and, if the drug is successful, will eventually be replaced.)

TNX-102 is a combination of:

  • Very Low-Dose Cyclobenzaprine: the drug in the muscle relaxant Flexeril, which a recent study suggests may improve sleep and other core symptoms of fibromyalgia when taken at bedtime in very low doses;
  • Lipids: naturally occurring substances in your cells that help with energy storage, signaling, and the structure of membranes.

The TONIX study involved 30 healthy subjects who took the medication at bedtime. It was meant only to gauge how the body processed the new formulation. Noting no severe or unexpected side effects, the company now plans to move forward with further development and testing.

In a press release, Chairman and President of TONIX said, "The results of this study provide us with valuable insights which will enable us to further advance our development programs targeting fibromyalgia and other challenging disorders of the central nervous system.... We are developing TNX-102 to be a fundamental advance in sleep hygiene and pain management and to be safer and more effective than currently available treatments."

The press release points out that disturbed sleep is a core feature of fibromyalgia and yet no "bedtime medication" is approved for it.

The road to FDA approval is long and complicated, meaning that even if all goes well, TNX-102 is unlikely to be on the market for several years.

However, cyclobenzaprine already is prescribed off-label for some people with fibromyalgia, especially when muscle spasms are a serious problem.

Have you taken cyclobenzaprine? Has it helped with your symptoms? Does it improve your sleep? Leave your comments here!

Learn more or join the conversation!

 

NEWSLETTER | FORUM | BIO | TWITTER | FACEBOOK

 

The above, with comments, originally appeared here.

 


 

blog comments powered by Disqus

Previous Previous Page